Innate Pharma SA has announced an update regarding the timing of the PACIFIC-9 Phase 3 trial data readout. The company revealed that AstraZeneca, which leads the trial, has shifted the expected timing for high-level data readout to the first half of 2027, a change from the previously anticipated second half of 2026. This delay underscores the event-driven nature of clinical trials, which can often face unforeseen challenges.

The PACIFIC-9 trial evaluates the efficacy of durvalumab in combination with either monalizumab or oleclumab in patients suffering from unresectable Stage III non-small cell lung cancer (NSCLC) who have not progressed after undergoing platinum-based chemoradiation therapy. Enrollment for this trial is now complete, marking a significant step in the study's progression.

Innate Pharma, headquartered in Marseille, France, is a clinical-stage biotechnology company specializing in immunotherapies for cancer patients. The company focuses on developing innovative antibody therapeutics, including its proprietary pipeline of antibody-drug conjugates (ADCs). Among its notable collaborations is the partnership with AstraZeneca, which includes the development of monalizumab, an anti-NKG2A antibody.

In the recent filing, Innate Pharma stated, "AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously." This adjustment reflects the complexities involved in the trial's design and execution.

The impact of this update may be felt across the industry, particularly among companies involved in similar therapeutic areas. As clinical timelines extend, firms may need to reassess their strategies and resource allocations in response to changing market dynamics.

Looking ahead, the filing does not specify what the next steps will be for Innate Pharma or the PACIFIC-9 trial, leaving stakeholders to await further announcements regarding the trial's progress and any subsequent developments.